Skip to main content
Fuan Pharmaceutical （Group）co.,Ltd logo

Fuan Pharmaceutical （Group）co.,Ltd — Investor Relations & Filings

Ticker · 300194 ISIN · CNE1000011G4 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,013 across all filing types
Latest filing 2021-08-27 Interim / Quarterly Rep…
Country CN China
Listing Shenzhen Stock Exchange 300194

About Fuan Pharmaceutical （Group）co.,Ltd

https://www.fapharm.com

Fuan Pharmaceutical (Group) Co., Ltd. is an integrated pharmaceutical enterprise specializing in the research, development, production, and distribution of a wide range of chemical drugs. The company operates across the entire value chain, encompassing pharmaceutical intermediates, active pharmaceutical ingredients (APIs), and finished dosage forms. Its product portfolio primarily focuses on anti-infectives, particularly cephalosporins and penicillins, as well as treatments for cardiovascular diseases, oncology, and respiratory conditions. Fuan Pharmaceutical maintains large-scale manufacturing facilities and emphasizes technological innovation to support its diverse pipeline of generic and specialized medications. The group serves both domestic and international markets, providing essential healthcare solutions through its network of subsidiaries and specialized production bases.

Recent filings

Filing Released Lang Actions
2021年半年度报告摘要
Interim / Quarterly Report Classification · 95% confidence The document is titled as a "2021 年半年度报告摘要" which translates to "2021 Semi-Annual Report Summary." It contains detailed financial data such as revenue, net profit, earnings per share, and asset information for the half-year period. It also discusses operational performance, R&D progress, market conditions, and management efforts during the reporting period. The presence of comprehensive financial metrics and business analysis indicates this is a substantive interim financial report rather than a brief announcement or summary. The document length is 4434 characters, which is slightly below 5000 characters, but the content is detailed and includes financial statements and analysis, meeting the criteria for an Interim / Quarterly Report (IR). Therefore, the document should be classified as an Interim / Quarterly Report (IR). H1 2021
2021-08-27 Chinese
2021年半年度报告披露提示性公告
Report Publication Announcement Classification · 100% confidence The document is a short announcement (295 characters) stating that the company's 2021 half-year report will be disclosed on a future date on a regulatory website. It does not contain the actual half-year financial report or substantive financial data, but merely informs investors about the upcoming publication. According to the 'MENU VS MEAL' rule, such a brief notice about report disclosure is classified as a Report Publication Announcement (RPA), not as the Interim/Quarterly Report (IR) itself.
2021-08-27 Chinese
关于子公司收到药品注册证书的公告
Regulatory Filings Classification · 95% confidence The document is a short announcement regarding the receipt of a drug registration certificate by the company's subsidiaries. It contains no financial statements, no detailed financial data, and no mention of annual or quarterly reporting. The document is an official company announcement about regulatory approval related to product registration, not a financial report or management discussion. The length is only 1036 characters, indicating it is a brief announcement rather than a full report. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2021-08-13 Chinese
关于子公司原料药通过CDE审批的公告
Regulatory Filings Classification · 95% confidence The document is a short announcement (802 characters) from a company about its subsidiary's drug raw material approval by the CDE (Center for Drug Evaluation). It contains no financial data, no detailed report, and no mention of financial results or management changes. It is an official announcement about regulatory approval of a product, not a financial report or meeting material. It does not fit into categories like Annual Report, Interim Report, or Earnings Release. It is a regulatory announcement about product approval, so it best fits under Regulatory Filings (RNS).
2021-08-09 Chinese
关于盐酸氨溴索注射液通过仿制药一致性评价的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by a company regarding the approval of a pharmaceutical product's consistency evaluation by a regulatory authority (国家药品监督管理局 - National Medical Products Administration). It contains no financial data, no mention of financial results, no management changes, no voting results, no legal proceedings, and no detailed financial or strategic presentation. The document is short (771 characters) and serves as a regulatory announcement about product approval and related risks. It does not fit into categories like Annual Report, Earnings Release, or Management Reports. It is best classified as a Regulatory Filing (RNS), which is the fallback for miscellaneous regulatory announcements that do not fit other categories.
2021-08-04 Chinese
关于盐酸昂丹司琼注射液通过仿制药一致性评价的公告
Regulatory Filings Classification · 95% confidence The document is a short announcement (706 characters) about a pharmaceutical product passing a regulatory evaluation for generic drug consistency. It includes a statement from the company and details about the product approval by the National Medical Products Administration. There is no financial data, no mention of a report being attached or published, and no indication of a meeting or voting results. The content is a regulatory announcement about product approval and market implications, which fits best under Regulatory Filings (RNS) as it does not match any other specific category such as financial reports, management changes, or capital updates.
2021-06-29 Chinese

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.